Newspatrolling.com News cum Content Syndication Portal Online
The Company’s Q4 PAT Rises 38.4%, Backed by 16.4% Revenue Growth and Expansion in EBITDA Margin
Mumbai, 29th May 2025: The unaudited financial statements for the quarter and full year ended March 31, 2025, have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
Key Consolidated Yearly Financial Highlights:
| Particulars | FY25 | FY24 |
| Revenues (in Rs Cr) | 696.48 | 570.37 |
| EBITDA (in Rs Cr) | 260.80 | 172.98 |
| EBITDA Margin | 37.4% | 30.3% |
| PAT (in Rs Cr) | 187.96 | 119.11 |
| PAT Margin | 27.0% | 20.9% |
| Quarterly EPS (in Rs) | 23.35 | 14.80 |
Key Highlights for FY25:
In FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 22% year-over-year increase, reaching Rs. 696.48 crore compared to Rs. 570.37 crore in FY24.
EBITDA for FY25 stood at Rs. 260.80 crore, with an EBITDA Margin of 37.4 %, as opposed to an EBITDA of Rs. 172.98 crore in FY24 with an EBITDA margin of 30.3%. This marks an improvement of 712 bps YoY.
Profit after Tax for FY25 stood at Rs. 187.96 crore, with a growth of 57.8% compared to Rs. 119.11 crore in FY24.
The PAT Margin stood at 27.0% in FY25, compared to 20.9% in FY24.
Key Consolidated Q4 Financial Highlights:
| Particulars | Q4 FY25 | Q4 FY24 |
| Revenues (in Rs Cr) | 184.11 | 158.18 |
| EBITDA (in Rs Cr) | 67.58 | 55.5 |
| EBITDA Margin | 36.7% | 35.1% |
| PAT (in Rs Cr) | 50.38 | 36.40 |
| PAT Margin | 27.4% | 23.0% |
| Quarterly EPS (in Rs) | 6.29 | 4.59 |
Key Highlights for Q4 FY25:
In the fourth quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 16.4 % year-over-year increase, reaching Rs. 184.11 crore compared to Rs. 158.18 crore in Q4 FY24.
EBITDA for Q4 FY25 stood at Rs. 67.58 crore, with an EBITDA Margin of 36.7 %, as opposed to an EBITDA of Rs. 55.5 crore in Q4 FY24 with an EBITDA margin of 35.1%. This marks an improvement of 162 bps YoY.
Profit after Tax for Q4 FY25 stood at Rs. 50.38 crore, with a growth of 38.4% compared to Rs. 36.40 crore in Q4 FY24.
The PAT Margin stood at 27.4% in Q4 FY25, compared to 23.0% in Q4 FY24.
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, “FY25 has been a landmark year for Supriya Lifescience, reflecting the strength of our diversified product portfolio, resilient global operations, and consistent focus on operational excellence. We achieved our highest-ever annual revenue of Rs. 697 crore, up 22% year-on-year, and delivered an EBITDA of Rs. 261 crore with a robust margin of 37.4%. In Q4FY25, revenue grew by 16.4% to Rs. 184.11 crore, while PAT rose by 38.4% to Rs. 50.38 crore, supported by improved margins. Our strategic focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive our performance. We remain committed to building on this momentum to deliver sustainable growth, foster innovation, and create long-term value for all stakeholders.”
